Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 3, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,430,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,575.50 pence per share; lowest price paid was 1,551 pence per share.
- Treasury Holdings (Settled): 484,364,412 shares (9.03% of total issued share capital).
- Treasury Holdings (Including Unsettled): 488,694,412 shares (10.01% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,881,356,960 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,430,000 shares. Consequently, the Company's treasury holdings increased to represent 10.01% of the total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total number of shares held in Treasury (484,364,412 settled) against the company's latest capitalization table.
- Confirm the percentage of voting rights held in Treasury (10.01% including unsettled shares) for disclosure threshold calculations under FCA rules.
- Note that the 4,881,356,960 shares in issue (excluding treasury) serve as the denominator for shareholder notification requirements.